CEO letter to shareholders
Melbourne, Australia, 19 September 2023 ASX: CUV Frankfurt Börse: UR9 Level 1...
Read More
Investor Webinar transcript
Melbourne, Australia, 30 August 2023 ASX: CUV Frankfurt Börse: UR9 Level 1...
Read More
CLINUVEL delivering on a long-term strategy with increase in annual revenues, profit
Melbourne, Australia, 29 August 2023 ASX: CUV XETRA-DAX: UR9 Level 1 ADR:...
Read More
Annual Results – Investor Webinar
Melbourne, Australia, 28 August 2023 ASX: CUV XETRA-DAX: UR9 Level 1 ADR:...
Read More
Afamelanotide Significantly Reduces DNA Damage in a Healthy Population
CLINUVEL has been awarded a five-year contract by the U.S. Department of...
Read More
SCENESSE® applied under five-year Veterans Affairs contract
CLINUVEL has been awarded a five-year contract by the U.S. Department of...
Read More
CLINUVEL secures IP for melanocortins to treat central nervous system disorders
CLINUVEL has secured a family of patents and patent applications relating to...
Read More
News Kommuniqué III
Melbourne, Australia, 26 June 2023 ASX: CUV XETRA-DAX: UR9 Level 1 ADR:...
Read More
Twilight Event - Briefing
CLINUVEL presented during a Twilight Briefing, after the close of market yesterday....
Read More
News Communiqué III
CLINUVEL’s News Communiqué III reviews the Company’s trajectory, and underlying reasons to...
Read More
News Kommuniqué II
Melbourne, Australia, 12 January 2023 ASX: CUV XETRA-DAX: UR9 Level 1 ADR:...
Read More
News Communiqué II
Download the PDF Authorised for ASX release by the Board of Directors...
Read More
News Communiqué I - Maestro Jaap van Zweden
Introducing CLINUVEL Intriguing Personality (CUVIP), Maestro Jaap van Zweden.
Read More
CLINUVEL launches CYACÊLLE, Next Generation Solar Care
Melbourne, Australia, 01 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More